Literature DB >> 8839661

Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics.

C B Eap1, T Finkbeiner, M Gastpar, N Scherbaum, K Powell, P Baumann.   

Abstract

METHODS: Twenty-two patients receiving (R)-methadone maintenance treatment were switched to a double dose of (R,S)-methadone: blood samples were collected before and after the change, and the concentrations of the enantiomers were measured. In the second period, during racemic methadone treatment, important interindividual variability in the stereoselective disposition of the enantiomers of methadone was measured, with (R)/(S) ratios ranging from 0.63 to 2.40. This point should be taken into account particularly with respect to therapeutic drug monitoring of racemic methadone.
RESULTS: A significant decrease P < 0.005 in the mean serum concentration/dose ratios of the active (R)-enantiomer before and after the change was measured (mean 3.97 and 3.33).
CONCLUSION: Although of small amplitude (16%), this decrease confirms previously described adaptive changes in methadone pharmacokinetics during racemic methadone maintenance treatment and may necessitate, in some patients, a dose adjustment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8839661     DOI: 10.1007/s002280050128

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

Authors:  A Rostami-Hodjegan; K Wolff; A W Hay; D Raistrick; R Calvert; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Toxicology and pathology of deaths related to methadone: retrospective review.

Authors:  S B Karch; B G Stephens
Journal:  West J Med       Date:  2000-01

Review 3.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia.

Authors:  Lili Aslostovar; Allison L Boyd; Mohammed Almakadi; Tony J Collins; Darryl P Leong; Rommel G Tirona; Richard B Kim; Jim A Julian; Anargyros Xenocostas; Brian Leber; Mark N Levine; Ronan Foley; Mickie Bhatia
Journal:  Blood Adv       Date:  2018-08-14

Review 5.  Pharmacogenetics of Methadone Response.

Authors:  Francina Fonseca; Marta Torrens
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

6.  A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio.

Authors:  D W Boulton; P Arnaud; C L DeVane
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

7.  Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients.

Authors:  Hartmut Stocker; Guido Kruse; Peter Kreckel; Christian Herzmann; Keikawus Arastéh; Jörg Claus; Heiko Jessen; Christiane Cordes; Bettina Hintsche; Frank Schlote; Lothar Schneider; Michael Kurowski
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

8.  Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure.

Authors:  Timothy B Mitchell; Kyle R Dyer; David Newcombe; Amy Salter; Andrew A Somogyi; Felix Bochner; Jason M White
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

9.  Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients.

Authors:  D J Foster; A A Somogyi; K R Dyer; J M White; F Bochner
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

10.  Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients.

Authors:  Chantal Csajka; Séverine Crettol; Monia Guidi; Chin B Eap
Journal:  Clin Pharmacokinet       Date:  2016-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.